B-cell type-patients tend to be older than patients with CLL with a median age in the 70’s.
B- cell type-usually present advanced disease with higher white blood cell counts and more massive splenomegaly and less pronounced adenopathy than patients with CLL.
B- cell type-patients respond poorly to chemotherapy with response rates less than 25% with rare complete responders.
B-cell type-median survival is 3 years.
B-cell-type-can arise associated a secondary transformation from CLL with a very poor survival.
T-cell type-rare postthymic malignancy with a median survival of 7.5 months.
T-cell type-monoclonal antibody to CD52 highly effective therapy.
T-cell type-deoxycoformin has a 40-50% objective response rate, with approximately 10% complete response.
T-cell type-usually present with massive splenomegaly, 40% with lymphadenopathy and 20% of patients with skin infiltration.